Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Octapharma Adds Track & Trace to Werum's PAS-X | Contract Pharma

What are you searching for?

Sign in
Breaking News

Octapharma Adds Track & Trace to Werum’s PAS-X

Will initially be operated in the packaging area for products for the Chinese market

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Octapharma has added the PAS-X Track & Trace Serialization Aggregation solution to Werum’s PAS-X at its production site in Vienna. Octapharma employs strict in-process quality control systems to ensure traceability, providing the complete documentation of the origin of all plasma products, their processing and distribution to countries worldwide.
 
PAS-X Track & Trace will initially be operated in the packaging area for the Chinese market. The serialization data provided by the Chinese authorities are loaded and the used data are reported back. PAS-X Track & Trace is interfaced to the existing PAS-X and exchanges order and stock data with the MES. The company plans to install Werum’s PAS-X Track & Trace at further packaging lines for different target countries in the Vienna site.
 
Octapharma develops and produces human proteins from human plasma and human cell-lines for haematology, immunotherapy and critical care therapies, and has five production facilities in Austria, France, Germany, Sweden and Mexico.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics